News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
396,766 Results
Type
Article (32501)
Company Profile (61)
Press Release (364204)
Section
Business (114723)
Career Advice (1369)
Deals (24197)
Drug Delivery (91)
Drug Development (60025)
Employer Resources (108)
FDA (9988)
Job Trends (9199)
News (213848)
Policy (25567)
Tag
Academia (1847)
Alliances (42304)
Alzheimer's disease (1040)
Approvals (9956)
Artificial intelligence (112)
Bankruptcy (231)
Best Places to Work (7735)
Breast cancer (148)
Cancer (1124)
Cardiovascular disease (86)
Career advice (1143)
CAR-T (79)
Cell therapy (223)
Clinical research (47814)
Collaboration (469)
Compensation (248)
COVID-19 (2456)
Data (1060)
Diabetes (153)
Diagnostics (3460)
Drug pricing (88)
Earnings (39754)
Employer resources (99)
Events (45477)
Executive appointments (227)
FDA (10541)
Funding (334)
Gene therapy (168)
GLP-1 (618)
Government (4048)
Healthcare (11485)
Infectious disease (2549)
Interviews (240)
IPO (10424)
Job creations (1815)
Job search strategy (989)
Layoffs (282)
Legal (7038)
Lung cancer (164)
Lymphoma (78)
Manufacturing (162)
Medical device (5894)
Medtech (5895)
Mergers & acquisitions (13976)
Metabolic disorders (436)
Neuroscience (1315)
NextGen: Class of 2025 (3735)
Non-profit (2786)
Northern California (1189)
Obesity (263)
Opinion (188)
Parkinson's disease (85)
Patents (97)
People (26040)
Phase I (14461)
Phase II (20774)
Phase III (16838)
Pipeline (473)
Policy (78)
Postmarket research (1862)
Preclinical (5979)
Radiopharmaceuticals (206)
Rare diseases (202)
Real estate (2622)
Regulatory (15851)
Research institute (1603)
Resumes & cover letters (209)
Southern California (957)
Startups (1988)
United States (9666)
Vaccines (607)
Weight loss (213)
Date
Today (44)
Last 7 days (437)
Last 30 days (1305)
Last 365 days (22345)
2025 (988)
2024 (22582)
2023 (25478)
2022 (33711)
2021 (36283)
2020 (34398)
2019 (28271)
2018 (21536)
2017 (20523)
2016 (18928)
2015 (21726)
2014 (16137)
2013 (12995)
2012 (13786)
2011 (14549)
2010 (13211)
Location
Africa (582)
Asia (25931)
Australia (4653)
California (2538)
Canada (953)
China (261)
Colorado (109)
Connecticut (114)
Europe (62241)
Florida (358)
Georgia (88)
Illinois (227)
Indiana (148)
Japan (77)
Maryland (508)
Massachusetts (1861)
Michigan (86)
Minnesota (105)
New Jersey (784)
New York (777)
North Carolina (403)
Northern California (1189)
Ohio (86)
Pennsylvania (580)
South America (810)
Southern California (957)
Texas (318)
Washington State (239)
396,766 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Deals
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.
June 20, 2024
·
10 min read
Press Releases
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
December 18, 2024
·
5 min read
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Drug pricing
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.
October 21, 2024
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
November 21, 2024
·
2 min read
·
Tristan Manalac
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
1 of 39,677
Next
